Association of the Tight Junction Protein Claudin-4 with Lung Function and Exacerbations in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) imposes a major healthcare burden. A tight junction protein, claudin-4 (CLDN4), may play a protective role in acute lung injury, but its role in COPD is unclear. To investigate the relationship between CLDN4 and COPD, we evaluated the association of CLDN4...

Full description

Saved in:
Bibliographic Details
Published in:International journal of chronic obstructive pulmonary disease 2021-01, Vol.16, p.2735-2740
Main Authors: Park, Shinhee, Lee, Pureun-Haneul, Baek, Ae Rin, Park, Jong Sook, Lee, Junehyuk, Park, Sung-Woo, Kim, Do Jin, Jang, An-Soo
Format: Article
Language:English
Subjects:
Acute respiratory distress syndrome
Analysis
Asthma
Biobanks
Blood
Body mass index
Chronic obstructive pulmonary disease
Claudin-4
Claudins
copd
Enrollments
Enzymes
Forced Expiratory Volume
Humans
Inflammation
Lung
Lung diseases, Obstructive
lung function
Male
Pathogenesis
Permeability
Plasma
Proteins
Pulmonary Disease, Chronic Obstructive - diagnosis
Respiratory diseases
Short Report
Smoking
Spirometry
Statistical analysis
Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic obstructive pulmonary disease (COPD) imposes a major healthcare burden. A tight junction protein, claudin-4 (CLDN4), may play a protective role in acute lung injury, but its role in COPD is unclear. To investigate the relationship between CLDN4 and COPD, we evaluated the association of CLDN4 with the clinical parameters of COPD, including exacerbations. We analyzed a cohort of 30 patients with COPD and 25 healthy controls and evaluated their clinical parameters, including lung function. The plasma CLDN4 level in stable and exacerbated COPD was measured. The COPD patients were all males and predominantly smokers; their initial lung function was poorer than the healthy controls. The mean CLDN4 plasma level was 0.0219 ± 0.0205 ng/mg in the control group, 0.0086 ± 0.0158 ng/mg in the stable COPD group (COPD-ST) and 0.0917 ± 0.0871 ng/mg in the exacerbated COPD (COPD-EXA) group. The plasma CLDN4 level was significantly lower in the COPD-ST than the control group, but was significantly elevated in the COPD-EXA group. The plasma CLDN4 level was inversely correlated with forced vital capacity and forced expiratory volume in 1 second in the COPD-EXA group (r=0.506, =0.001 and r=0.527,
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S330674